Evidence Level:Sensitive: C3 – Early Trials
Title:
Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3ß) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors.
Excerpt:One BRAFV600K-mutated melanoma with > 20 brain metastases, post checkpoint/BRAF/MEK failure has an ongoing CR starting at cycle 2 and sustained after 9 months on treatment.
DOI:10.1200/JCO.2020.38.15_suppl.3507